{"id":"W3012894524","doi":"10.1007/s13555-020-00367-x","title":"Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Guenther Dermatology Research Centre","funders":"Cilag; LEO Pharma; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; Biogen; Pfizer; Incyte; Fresenius Medical Care North America; Sun Pharma; Dermira; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Medac; Baxalta; Hexal AG; Celgene; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Ixekizumab; Medicine; Dosing; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Imputation (statistics); Internal medicine; Randomized controlled trial; Quality of life (healthcare); Tolerability; Adverse effect; Dermatology; Secukinumab; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01017592,0.0009043929,0.003163256,0.0003910409,0.0006051778,0.001733078,0.0007713281,0.001869252,0.003005886],"category_scores_gemma":[0.008021933,0.0004484126,0.005292985,0.0006854577,0.0007037011,0.0009690981,0.0004101451,0.002246356,0.0005326112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006855874,"about_ca_system_score_gemma":0.00169115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004774307,"about_ca_topic_score_gemma":0.001085763,"domain_scores_codex":[0.9955159,0.002441027,0.0006412419,0.0005564258,0.0005476302,0.0002977712],"domain_scores_gemma":[0.9924765,0.003042702,0.002512337,0.0005510353,0.0006896973,0.0007277331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.915887,0.004495169,0.007399797,0.00461523,0.01046981,0.00009385047,0.000101698,0.0004075897,0.002108226,0.0001636435,0.00301877,0.05123931],"study_design_scores_gemma":[0.8069855,0.1237764,0.04373942,0.0013062,0.01571199,0.0002941101,0.00007710853,0.0006697437,0.001573772,0.0005580256,0.005226899,0.00008083209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8875131,0.09318783,0.002311602,0.001812981,0.0007114927,0.004636954,0.005922943,0.0001966984,0.003706342],"genre_scores_gemma":[0.9578102,0.02167205,0.003130158,0.002494813,0.001045078,0.006046674,0.005729076,0.00004099608,0.002030954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01017592,"threshold_uncertainty_score":0.05381602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03507305455433154,"score_gpt":0.2892764760050546,"score_spread":0.2542034214507231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}